ECSP22087958A - Compuestos de insulina acilada de acción temporal prolongada - Google Patents

Compuestos de insulina acilada de acción temporal prolongada

Info

Publication number
ECSP22087958A
ECSP22087958A ECSENADI202287958A ECDI202287958A ECSP22087958A EC SP22087958 A ECSP22087958 A EC SP22087958A EC SENADI202287958 A ECSENADI202287958 A EC SENADI202287958A EC DI202287958 A ECDI202287958 A EC DI202287958A EC SP22087958 A ECSP22087958 A EC SP22087958A
Authority
EC
Ecuador
Prior art keywords
compounds
acylated insulin
long
insulin compounds
acting
Prior art date
Application number
ECSENADI202287958A
Other languages
English (en)
Inventor
David Benjamin Flora
Valdislav Kisselev
Seamus Patrick Brennan
Francisco Alcides VALENZUELA
Wen Liu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22087958A publication Critical patent/ECSP22087958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos descritos en la presente se refieren al tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilada de acción temporal prolongada que reducen la glucosa en sangre, composiciones farmacéuticas que contienen tales compuestos, usos terapéuticos de tales compuestos y un compuesto intermediario usado para fabricar los compuestos de insulina acilada.
ECSENADI202287958A 2020-05-15 2022-11-15 Compuestos de insulina acilada de acción temporal prolongada ECSP22087958A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063025463P 2020-05-15 2020-05-15

Publications (1)

Publication Number Publication Date
ECSP22087958A true ECSP22087958A (es) 2022-12-30

Family

ID=78524979

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202287958A ECSP22087958A (es) 2020-05-15 2022-11-15 Compuestos de insulina acilada de acción temporal prolongada

Country Status (16)

Country Link
US (1) US20230174609A1 (es)
EP (1) EP4149516A1 (es)
JP (1) JP7456007B2 (es)
KR (1) KR20230009499A (es)
CN (1) CN115867308A (es)
AU (1) AU2021273262A1 (es)
BR (1) BR112022022885A2 (es)
CA (1) CA3177905A1 (es)
CL (1) CL2022003187A1 (es)
CO (1) CO2022016338A2 (es)
CR (1) CR20220641A (es)
EC (1) ECSP22087958A (es)
IL (1) IL297976A (es)
MX (1) MX2022014309A (es)
PE (1) PE20230832A1 (es)
WO (1) WO2021231676A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US20170008928A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل

Also Published As

Publication number Publication date
EP4149516A1 (en) 2023-03-22
US20230174609A1 (en) 2023-06-08
CN115867308A (zh) 2023-03-28
BR112022022885A2 (pt) 2022-12-20
CO2022016338A2 (es) 2022-11-29
AU2021273262A1 (en) 2022-12-08
IL297976A (en) 2023-01-01
KR20230009499A (ko) 2023-01-17
CL2022003187A1 (es) 2023-03-03
WO2021231676A1 (en) 2021-11-18
JP7456007B2 (ja) 2024-03-26
JP2023526069A (ja) 2023-06-20
CA3177905A1 (en) 2021-11-18
MX2022014309A (es) 2022-12-07
CR20220641A (es) 2023-01-19
PE20230832A1 (es) 2023-05-19

Similar Documents

Publication Publication Date Title
CO2022016338A2 (es) Compuestos de insulina acilada de acción temporal prolongada
ECSP19083930A (es) Compuesto de insulina acilada
CL2021003012A1 (es) Inhibidores del inflamasoma nlrp3
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
CL2023000086A1 (es) Análogos de insulina novedosos y usos de estos(div 202201400)
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
DOP2009000284A (es) Compuestos de tiazolopiridina moduladores de sirtuina
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
CL2009000381A1 (es) Compuestos derivados de tiazol o tiazol-5-carboxamida, inhibidores de la actividad estearoil-coa-desaturasa humana (scd); composicion farmaceutica; y uso para el tratamiento de un trastorno o enfermedad mediada por las enzimas de scd, tal como diabetes, obesidad, enfermedad cardiovascular, lipidos elevados, entre otras.
CO6640324A2 (es) Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
UY38986A (es) Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO6511248A2 (es) Cocristales de tramadol y coxibs
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
BRPI0916507A8 (pt) Compostos, composição cosmética, processo de tratamento cosmético não terapêutico da pele e usos não terapêuticos de uma composição cosmética
ECSP24000004A (es) Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos
BR112012007991B8 (pt) uso de inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas
AR038046A1 (es) Derivados de acidos 3-fenil-2-arilalquiltiopropionicos moduladores de ppar alfa
UY36354A (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
ECSP23076800A (es) Derivados de pirazolopiridina y sus usos
AR036677A1 (es) Uso de aminometilcromanos sustituidos para la elaboracion de un medicamento, un procedimiento para la preparacion de estos compuestos y las composiciones farmaceuticas que contienen estos compuestos en calidad de principios activos